The World Health Organisation (WHO), in its first global guidelines on Glucagon-Like Peptide-1 (GLP-1) therapies for obesity, has said these drugs must be used alongside intensive behavioural interventions—including a healthy diet, regular physical activity, and ongoing professional support.

Originally developed for type 2 diabetes, GLP-1 therapies mimic gut hormones to control blood sugar, reduce appetite, and slow digestion. In India, the recent launch of Mounjaro and Wegovy has quickly pushed these medications into the list of top-selling brands.

Releasing its guidance on Monday, WHO said obesity is a chronic, relapsing disease affecting every country and linked to 3.7 million deaths worldwide in 2024. Without urgent action, the number of people living with obesity is projected to dou

See Full Page